Browsing by 저자 : Yoon-Koo Kang
전체 결과 17건 중 1-17 번을 표시중입니다.
-
1
Article
A frst-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
Stephen L Chan
;
Martin Schuler
;
Yoon-Koo Kang
;
et al
2022
-
2
Article
A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours
Hyung-Don Kim
;
Changhoon Yoo
;
Min-Hee Ryu
;
et al
2023
-
3
Article
Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis
Sora Kang
;
Min-Hee Ryu
;
Yeong Hak Bang
;
et al
2022
-
4
Article
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
Yoon-Koo Kang
;
Martin Reck
;
Paul Nghiem
;
et al
2022
-
5
Article
Association between HER2 heterogeneity and clinical outcomes of HER2?positive gastric cancer patients treated with trastuzumab
Kyunghye Bang
;
Jaekyung Cheon
;
Young Soo Park
;
et al
2022
-
6
Article
Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib
Yeong Hak Bang
;
Min-Hee Ryu
;
Hyung-Don Kim
;
et al
2022
-
7
Article
Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study
Hyung-Don Kim
;
Jong Seok Lee
;
Young Soo Park
;
et al
2022
-
8
Article
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
Yoon-Koo Kang
;
Satoshi Morita
;
Taroh Satoh
;
et al
2022
-
9
Article
Insertion-deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab
Hyung-Don Kim
;
Min-Hee Ryu
;
Young Soo Park
;
et al
2022
-
10
Article
Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions
Yoon-Koo Kang
;
Hyung-Don Kim
;
Hyun Jin Kim
;
et al
2023
-
11
Article
Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach
Seong-Ho Kong
;
Yukinori Kurokawa
;
Jeong-Hwan Yook
;
et al
2023
-
12
Article
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang
;
Li-Tzong Chen
;
Min-Hee Ryu
;
et al
2022
-
13
Article
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients
Hyun Cheol Chung
;
Yoon-Koo Kang
;
Zhendong Chen
;
et al
2022
-
14
Article
Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial
Jwa Hoon Kim
;
Min-Hee Ryu
;
Young Soo Park
;
et al
2022
-
15
Article
Prognostic value of natural killer cell activity for patients with HER2+advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab
Hyungwoo Cho
;
Min-Hee Ryu
;
Hyung Eun Lee
;
et al
2022
-
16
Article
Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study
Hyung-Don Kim
;
Jong Seok Lee
;
Jeong Hwan Yook
;
et al
2022
-
17
Article
Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)
Min-Hee Ryu
;
Kyung Hee Lee
;
Lin Shen
;
et al
2023